

Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

**Ref**: FOI-022024-000647

Date:

Address / Email:

Dear

## Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 27 patients
- Abemaciclib + Fulvestrant 0 patients
- Alpelisib + Fulvestrant 0 patients
- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 patients
- Atezolizumab +Nab-paclitaxel/Paclitaxel 0 patients
- Capecitabine as a single agent 8 patients
- Eribulin as a single agent or in combination 1 patients
- Everolimus + Exemestane 0 patients
- Fulvestrant as a single agent 12 patients
- Lapatinib 0 patients
- Neratinib 2 patients
- Parp Inhibitors (Olaparib/Talazoparib) 0 patients
- Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 44 patients
- Palbociclib + Fulvestrant 0 patients
- Pembrolizumab 6 patients
- Platinum (e.g. carboplatin or cisplatin) as a single agent 0 patients
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 12 patients
- Ribociclib + Fulvestrant 0 patients
- Sacituzumab Govitecan 6 patients
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 27 patients
- Taxane and/or Anthracycline in combination 18 patients
- Trastuzumab as a single agent or in combination 68 patients
- Trastuzumab emtansine 9 patients
- Transtuzumab deruxtecan 9 patients
- Any other active systemic anti-cancer therapy 35 patients

Ref: FOI-022024-000647

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Add-Aspirin - 38 patients on Breast cohort.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager Trust Headquarters Russell's Hall Hospital Dudley West Midlands DY1 2HQ

Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF

Tel: 0303 123 1113 www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust